Literature DB >> 6553512

Restoration by levamisole of immune responses suppressed in tumor-bearing mice.

M Shiraishi, K Himeno, K Nomoto.   

Abstract

Restorative effects of levamisole on suppressed immune responses were observed in BALB/c mice inoculated with a syngeneic methylcholanthrene-induced fibrosarcoma and immunized with nucleated chicken erythrocytes. In tumor-bearing mice, cell-mediated cytotoxicity, delayed footpad reaction, and antibodies were suppressed, and only the delayed footpad reaction was restored by levamisole. Suppressive effects in tumor-bearing mice can be transferred with sera or spleen cells, and the expression of suppressive effects cannot be abolished by treatment of the recipients with levamisole. However, the generation of suppressor mechanisms was affected by treatment of tumor-bearing donors with levamisole.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6553512     DOI: 10.1007/bf00199702

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  28 in total

1.  Effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease.

Authors:  B Ramot; M Biniaminov; C Shoham; E Rosenthal
Journal:  N Engl J Med       Date:  1976-04-08       Impact factor: 91.245

2.  Effects of levamisole and imidazole on lymphocyte proliferation and cyclic nucleotide levels.

Authors:  J W Hadden; R G Coffey; E M Hadden; E Lopez-Corrales; G H Sunshine
Journal:  Cell Immunol       Date:  1975-11       Impact factor: 4.868

3.  Allogeneic tumor enhancement by levamisole, a new immunostimulatory compound: studies on cell-mediated immunity and humoral antibody response.

Authors:  A Mantovani; F Spreafico
Journal:  Eur J Cancer       Date:  1975-08       Impact factor: 9.162

4.  Inhibition by levamisole of metastases by cells transformed by herpes simplex virus type I.

Authors:  J M Sadowski; F Rapp
Journal:  Proc Soc Exp Biol Med       Date:  1975-05

5.  Immunological phagocytosis: effect of drugs on phosphodiesterase activity.

Authors:  A Oliveira Lima; M Q Javierre; W Dias da Silva; D Sette Camara
Journal:  Experientia       Date:  1974-08-15

6.  Letter: Impaired neutrophil phagocytosis.

Authors:  J De Cree; H Verhaegen; W De Cock; R Vanheule; J Brugmans; V Schuermans
Journal:  Lancet       Date:  1974-08-03       Impact factor: 79.321

7.  Augmentation of chemotherapeutically induced remission of a murine leukemia by a chemical immunoadjuvant.

Authors:  M A Chirigos; J W Pearson; J Pryor
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

8.  Letter: Levamisole.

Authors:  D J Webster; L E Hughes
Journal:  Lancet       Date:  1975-04-19       Impact factor: 79.321

9.  L-tetramisole. Enhancement of human lymphocyte response to antigen.

Authors:  H F Pabst; J Crawford
Journal:  Clin Exp Immunol       Date:  1975-09       Impact factor: 4.330

10.  Effects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems.

Authors:  R K Johnson; D P Houchens; M R Gaston; A Goldin
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug
View more
  1 in total

1.  Avirulent mutants of Macrophomina phaseolina and Aspergillus fumigatus initiate infection in Phaseolus mungo in the presence of phaseolinone; levamisole gives protection.

Authors:  S Sett; S K Mishra; K A Siddiqui
Journal:  J Biosci       Date:  2000-03       Impact factor: 1.826

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.